SCHEMBL29647894

SCHEMBL29647894

CN(CCCSc1cccc(Br)c1)C(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 2/20 0.38
KDM4E B2RXH2 1/20 0.38
PDK2 Q15119 1/20 0.38
RIPK1 Q13546 1/20 0.38
MAOA P21397 1/20 0.37
HTR2C P28335 1/20 0.36
SLC6A4 P31645 1/20 0.36
POLB P06746 1/20 0.36
FDPS P14324 1/20 0.36
FPR3 P25089 1/20 0.35
FPR2 P25090 1/20 0.35
TSHR P16473 1/20 0.35
TRPV4 Q9HBA0 1/20 0.35
HSP90AA1 P07900 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
AAK1 Q2M2I8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24591933 1.00 ALDH1A1 (0.39) ALDH1A1KMT2AMAPTLMNAKDM4E
SCHEMBL21552142 0.82 ALDH1A1 (0.47) ALDH1A1KMT2AMAPTLMNAKDM4E
SCHEMBL26830762 0.81 ALDH1A1 (0.45) ALDH1A1KMT2ALMNAKDM4EPDK2
SCHEMBL7016584 0.78 FDPS (0.41) KDM4EPDK2HTR2CSLC6A4FDPS
SCHEMBL26686410 0.76 TRPV4 (0.42) ALDH1A1KMT2AMAPTKDM4EPDK2
SCHEMBL3012881 0.76 TAAR1 (0.55) ALDH1A1LMNAKDM4ERIPK1HTR2C
SCHEMBL29647929 0.75 KMT2A (0.39) ALDH1A1KMT2AMAPTLMNAKDM4E
SCHEMBL24591935 0.75 KMT2A (0.39) ALDH1A1KMT2AMAPTLMNAKDM4E
SCHEMBL23420055 0.75 L3MBTL1 (0.46) ALDH1A1LMNAKDM4EPDK2RIPK1
SCHEMBL3346137 0.74 MAOA (0.44) ALDH1A1MAPTKDM4EMAOAAAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497460-B2 Anti-MSR1 antibodies and methods of use thereof REGENERON PHARMACEUTICALS, INC. (US) 2025-12-16 US disclosed
US-20230079407-A1 ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. 2023-03-16 US disclosed
US-11377502-B2 Anti-MSR1 antibodies and methods of use thereof REGENERON PHARMACEUTICALS, INC. (US) 2022-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079407-A1 ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF CD47, MSR1, LDLR ALDH1A1 3728/4885KMT2A 710/4885MAPT 4571/4885
US-12497460-B2 Anti-MSR1 antibodies and methods of use thereof CD47, MSR1, LDLR ALDH1A1 3728/4885KMT2A 710/4885MAPT 4571/4885
US-11377502-B2 Anti-MSR1 antibodies and methods of use thereof CD47, MSR1, LDLR ALDH1A1 3728/4885KMT2A 710/4885MAPT 4571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.